Experience With the Use of Continuous Glucose Monitoring (CGM) Devices in People With Type 2 Diabetes Mellitus

Launched by FUNDACIO D'INVESTIGACIO EN ATENCIO PRIMARIA JORDI GOL I GURINA · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the experiences of people with type 2 diabetes who use continuous glucose monitoring (CGM) devices. These devices help monitor blood sugar levels in real-time, which can be very helpful for managing diabetes. The study aims to gather insights from individuals who have been using a CGM device daily for at least 12 months, particularly looking at what they find helpful and what challenges they face with the device.

To be eligible for the study, participants must have been using a CGM sensor for diabetes management and be on an intensive insulin therapy plan that includes multiple daily insulin doses. The researchers will conduct individual interviews to learn about the participants' experiences. This information will help healthcare providers understand how to better support patients with diabetes and decide if CGM devices should be made available to more people. It's important to know that the study is not yet recruiting participants and is specifically looking for adults who can communicate in either Catalan or Spanish.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have been using a CGM sensor daily for diabetes management for the past 12 months or more.
• • Treatment with intensive insulin therapy (basal bolus regimen with 3 or more daily doses of insulin).
• • Agree to participate in the study.
• Exclusion Criteria:
• • Cognitive impairment measured by the SPMSQ test with a score of 3 or more errors.
• • Being institutionalised.
• • Have another person responsible for monitoring the device and making decisions related to diabetes (insulin adjustment, carbohydrate rations, etc.).
• • Language difficulty: not being able to hold a fluent conversation in Catalan or Spanish for 30-60 minutes.